{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:15:17Z","timestamp":1790111717050,"version":"4.0.1"},"reference-count":12,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,2,12]],"date-time":"2007-02-12T00:00:00Z","timestamp":1171238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Vitiligo is a common pigmentary disorder with great cosmetic and psychological morbidity. No treatment available is a definitive cure. Systemic psoralen and ultraviolet A (PUVA) has been the mainstay of treatment. Narrow\u2010band ultraviolet B (NB\u2010UVB) has been recently introduced. Although retrospective comparative study of systemic PUVA and NB\u2010UVB has been published from our centre, no prospective study has been reported to date.<\/jats:p><jats:p><jats:bold>Aims\u2002<\/jats:bold> To investigate the position of NB\u2010UVB vis\u2010\u00e0\u2010vis PUVA in terms of efficacy, time to repigment and adverse effects and to help decide if one therapy has an advantage over another in the treatment of vitiligo.<\/jats:p><jats:p><jats:bold>Subjects and methods\u2002<\/jats:bold> It was a randomized, open, prospective study of 50 patients divided equally in TMP PUVA and NB\u2010UVB groups. The study period was from January 2004 to June 2005.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The mean degree of repigmentation attained in the NB\u2010UVB group was 52.24% over a mean treatment period of 6.3\u00a0months, whereas in the PUVA group it was 44.7% in a mean period of 5.6\u00a0months (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.144). After excluding the results of therapy\u2010resistant sites, that is, hands and feet, the mean degree of repigmentation in the NB\u2010UVB group was 67.57%, whereas in the PUVA group it was 54.2% (<jats:italic>P\u00a0=<\/jats:italic>\u00a00.007).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> NB\u2010UVB performed better in comparison to TMP PUVA in terms of mean total repigmentation when traditionally considered therapy\u2010resistant sites were excluded.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2006.02035.x","type":"journal-article","created":{"date-parts":[[2007,2,12]],"date-time":"2007-02-12T09:48:12Z","timestamp":1171273692000},"page":"638-642","source":"Crossref","is-referenced-by-count":71,"title":["Comparison of systemic PUVA and NB\u2010UVB in the treatment of vitiligo: an open prospective study"],"prefix":"10.1111","volume":"21","author":[{"given":"A","family":"Bhatnagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AJ","family":"Kanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Parsad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,3,22]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.114752"},{"key":"e_1_2_5_3_2","first-page":"651","article-title":"A preliminary clinical report on the treatment of leucoderma with Ammi Majjus Linn","volume":"31","author":"El Mofty AM","year":"1948","journal-title":"J Eygpt Med Assoc"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb07096.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1988.tb03489.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890480045006"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01413.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1959.40"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.12.1532"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(00)90133-6"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02329.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01837.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06128.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2006.02035.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2006.02035.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:37:18Z","timestamp":1696966638000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2006.02035.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,22]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1468-3083.2006.02035.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.02035.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,22]]}}}